| 1163345 |
Germany |
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories
|
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
Virus Genome Detection – SARS-CoV-2 sequence analysis (417)
[Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)]
|
2025-11-20 |
|
|
| PT name |
(Virus Genome Detection – SARS-CoV-2 sequence analysis (417)) |
| Scheme name in national language |
(Virusgenom-Nachweis - SARS-CoV-2 Sequenzanalyse (417)) |
| Tested property |
(Differentiation of SARS-CoV-2 variants with clinical relevance using whole genome sequencing) |
|
| 1271426 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
Virus nucleic acid determination: SARS-CoV-2
[Vírus nukleinsav meghatározás: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus nucleic acid determination: SARS-CoV-2) |
| Remarks |
(amplification techniques (NAT) for qualitative determination of SARS-CoV-2 virus. Qualitative results are) |
| Scheme name in national language |
(Vírus nukleinsav meghatározás: SARS-CoV-2) |
|
| 1271523 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
POCT: SARS-CoV-2
[POCT: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(POCT: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG, IgM, total antibody) and antigen determination) |
| Scheme name in national language |
(POCT: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total qualitative) (Anti-SARS-CoV-2 - IgG qualitative) (Anti-SARS-CoV-2 - IgM qualitative) (SARS-CoV-2 Antigen qualitative) (SARS-CoV-2 interpretation) |
|
| 1271562 |
Hungary |
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
QualiCont In Vitro Diagnostic Quality Control Nonprofit Ltd.
|
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
Virus serology: SARS-CoV-2
[Vírus szerológia: SARS-CoV-2]
|
2026-03-19 |
|
|
| PT name |
(Virus serology: SARS-CoV-2) |
| Remarks |
(The content of the scheme: SARS-CoV-2 antibody (IgG-, IgG-S, IgG-N, IgM, IgA, total antibody) |
| Scheme name in national language |
(Vírus szerológia: SARS-CoV-2) |
| Tested property |
(Anti-SARS-CoV-2 total (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-S (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG-N (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgG (OD, S/CO, quantitative, evaluation)) (Anti-SARS-CoV-2 – IgM (OD, S/CO, quantitative, evaluation)) |
|
| 1144039 |
United Kingdom |
Weqas
Weqas
|
POCT Respiratory Virus
[POCT Respiratory Virus]
POCT Respiratory Virus
[POCT Respiratory Virus]
|
2026-04-20 |
|
|
| Remarks |
(targeted for Influenza A (and subtypes) Influenza B, SARS-Cov-2, and Respiratory Syncytial Virus) (buffer which may contain Influenza A (either / both H1N1 and H3N2 subtypes), influenza B, RSV, SARS) (supplied ready to use; no pre-analytical preparation is required.
- Qualitative reporting for SARS-CoV-2) |
| Tested property |
(SARS-CoV-2 Ag (RNA)) |
|
| 705717 |
Brazil |
ControlLab Controle de Qualidade para Laboratórios Ltda
ControlLab Controle de Qualidade para Laboratórios Ltda
|
Clinical PT - Molecular Biology Coronavírus (SARS-CoV2)
[EP Clínico - Biologia Molecular Coronavírus (SARS-CoV2)]
Clinical PT - Molecular Biology Coronavírus (SARS-CoV2)
[EP Clínico - Biologia Molecular Coronavírus (SARS-CoV2)]
|
2026-05-13 |
|
|
| PT name |
(Clinical PT - Molecular Biology Coronavírus (SARS-CoV2)) |
| Scheme name in national language |
(EP Clínico - Biologia Molecular Coronavírus (SARS-CoV2)) |
| Tested property |
(Coronavírus (SARS-CoV2)) (Sequencing: Coronavirus (SARS-CoV2) - identification) (Sequencing: Coronavirus (SARS-CoV2) - Similarity Index (%)) |
|
